MP29-02: a breakthrough for the treatment of allergic rhinitis.
about
A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis.Focusing the mechanism of action to dissect the different treatments of respiratory allergy.Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis.MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis.Confounders of severe asthma: diagnoses to consider when asthma symptoms persist despite optimal therapy
P2860
MP29-02: a breakthrough for the treatment of allergic rhinitis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
MP29-02: a breakthrough for the treatment of allergic rhinitis.
@en
type
label
MP29-02: a breakthrough for the treatment of allergic rhinitis.
@en
prefLabel
MP29-02: a breakthrough for the treatment of allergic rhinitis.
@en
P2860
P1476
MP29-02: a breakthrough for the treatment of allergic rhinitis.
@en
P2093
Jonathan A Bernstein
P2860
P304
P356
10.1517/14656566.2013.828693
P407
P577
2013-08-26T00:00:00Z